VisionTech Portfolio Company Toralgen Closes $1.9M Seed Funding Round

INDIANAPOLIS, IN., September 10, 2019 – Toralgen, Inc., an Indiana-based biotechnology company, announced the closure of its seed funding round, raising more than $1.9 million.

Participants in the round include VisionTech Angels, Elevate Ventures, and Solyco Advisors as well as investors and strategic partners with deep domain expertise. 


About Toralgen, Inc.
Toralgen, Inc. is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. Its poly-bile nanoparticle platform eliminates many of the inherent challenges of biologics and has the potential to improve outcomes through optimized drug delivery. Toralgen is currently studying treatments for diabetes and autoimmune disorders. For information or to inquire about possible collaborations, visit our website.

Contact: Dave Moore, Toralgen,